Safety and Efficacy of Re-Immunization with Inactivated Vaccines in Multiple Myeloma Patients on Lenalidomide Maintenance Following Autologous Hematopoietic Stem Cell Transplantation (Auto HCT)
Year: 2017
Type: article
Abstract: Introduction: Lenalidomide maintenance (LM) is the standard of care for multiple myeloma (MM) patients after Auto HCT to prolong progression free survival. Although CDC guidelines recommend vaccination starting 12 months after HCT, there is varying practice amongst institutions regarding revaccination in patients on maintenance therapy, with some not vaccinating at all. Due to decreased vaccine rates among the general population causing decreases in herd immunity, we aim to establish the safety and efficacy of revaccinating patients on LM.
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W2589530531